Research Article
Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Table 1
Distribution of patients according to demographic and clinical variables.
| | Demographic and clinical characteristics | Locally advanced () | Metastatic () | Recurrent () |
| | Age (years) | | | | | | | | | | Min–Max | 41-82 | 38-83 | 52-70 | | Weight (kg) | | | | | | | | | | Min–Max | 42-86 | 29-85 | 56-85 | | Sex (no., %) | Female | 8 (34.8) | 15 (35.7) | 1 (25.0) | | Male | 15 (65.2) | 27 (64.3) | 3 (75.0) | | Skin color (no., %) | White | 14 (60.9) | 30 (71.4) | 1 (25.0) | | Black | 4 (17.4) | 9 (21.4) | 1 (25.0) | | Mixed | 5 (21.7) | 3 (7.1) | 2 (50.0) | | ECOG (no., %) | 0 | 10 (43.5) | 11 (26.2) | — | | 1 | 10 (43.5) | 22 (52.4) | 4 (100) | | 2 | 3 (13.0) | 9 (21.4) | — | | Tumor location (no., %) | Head | 15 (65.2) | 19 (45.2) | 3 (75) | | Body | 2 (8.7) | 4 (9.5) | — | | Tail | — | 7 (16.7) | — | | Mixed | 6 (26) | 12 (28.6) | 1 (25) |
|
|
SD: standard deviation; QR: quartile range.
|
